Teacher Retirement System of Texas Trims Holdings in Eli Lilly and Company $LLY

Teacher Retirement System of Texas decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 290,865 shares of the company’s stock after selling 13,379 shares during the period. Eli Lilly and Company accounts for about 0.9% of Teacher Retirement System of Texas’ holdings, making the stock its 13th largest holding. Teacher Retirement System of Texas’ holdings in Eli Lilly and Company were worth $221,930,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Hudson Value Partners LLC raised its holdings in shares of Eli Lilly and Company by 13.1% during the third quarter. Hudson Value Partners LLC now owns 2,770 shares of the company’s stock valued at $2,114,000 after acquiring an additional 321 shares in the last quarter. UNIVEST FINANCIAL Corp boosted its holdings in Eli Lilly and Company by 24.2% in the third quarter. UNIVEST FINANCIAL Corp now owns 34,297 shares of the company’s stock valued at $26,169,000 after acquiring an additional 6,678 shares in the last quarter. Kingdom Financial Group LLC. purchased a new position in Eli Lilly and Company during the 3rd quarter valued at $492,000. Vantage Investment Partners LLC raised its holdings in Eli Lilly and Company by 5.8% in the 3rd quarter. Vantage Investment Partners LLC now owns 51,825 shares of the company’s stock worth $39,542,000 after purchasing an additional 2,819 shares in the last quarter. Finally, Coign Capital Advisors LLC raised its holdings in Eli Lilly and Company by 8.4% in the 3rd quarter. Coign Capital Advisors LLC now owns 855 shares of the company’s stock worth $652,000 after purchasing an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LLY. Jefferies Financial Group lifted their target price on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Truist Financial upped their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Zacks Research raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Morgan Stanley lifted their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Finally, HSBC reaffirmed a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Four research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company Stock Up 0.8%

Shares of NYSE:LLY opened at $1,087.63 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a fifty day simple moving average of $1,056.39 and a two-hundred day simple moving average of $878.04. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The stock has a market capitalization of $1.03 trillion, a price-to-earnings ratio of 53.21, a PEG ratio of 0.81 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA granted Breakthrough Therapy designation for Lilly’s ovarian cancer candidate (sofetabart/mipitecan), improving the odds of faster development and a premium approval pathway for a novel oncology asset. Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
• Positive Sentiment: Lilly launched a Phase 3b dosing study for retatrutide (obesity candidate), a near-term program de‑risk step that could support label expansion and broaden commercial use if results are favorable. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Data/real‑world studies continue to support obesity and metabolic franchises: SURMOUNT‑REAL UK (tirzepatide real‑world) updates and a retatrutide osteoarthritis signal suggest incremental clinical and commercial benefits beyond weight loss. These help underpin revenue upside for GLP/GIP drugs. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Lilly expanded its oncology imaging footprint with a new Phase 1 PET tracer study, signaling diversification into diagnostics/precision oncology that can boost long‑term margins and pipeline value. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Positive Sentiment: Executives at the JPMorgan Healthcare Conference reiterated that the obesity market will evolve to include more pill options, combos and better access — a structural message that supports multi‑year demand growth for Lilly’s metabolic portfolio. What obesity drugmakers see next in the market: More pills, easier access and drug combinations
• Neutral Sentiment: Lilly confirmed its fourth‑quarter 2025 earnings release and conference call for Feb. 4 — a scheduled event that will likely drive near‑term volatility as investors re‑assess guidance and sales cadence. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Organizational update: Lilly appointed Pranav Shroff as director of marketing — a routine personnel move with limited near‑term financial impact but relevant for commercial execution. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Competition risk in key international markets: Sun Pharma won approval for a Wegovy generic in India, intensifying price and market‑share pressure in a top growth region and foreshadowing similar generic/biologic competition scenarios. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market as Sun Pharma Wins Wegovy Generic Nod
• Negative Sentiment: Legal/political overhang: coverage cites a lawsuit and public scrutiny over insulin pricing that can bring reputational and financial risk if litigation expands or results in penalties. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.